NewLimit Reaches $3 Billion Valuation After $435 Million Funding Round
NewLimit raised $435 million in a Series C led by Founders Fund at a $3.1 billion valuation, and the company states its first drug for alcohol-related liver disease is expected to enter clinical trials next year.
Fact Check
All core facts are confirmed by multiple independent sources. StatNews and Endpoints News (both primary biotech industry outlets) and FirstWord Pharma confirm: $435M Series C, Founders Fund as lead, $3.1B post-money valuation, and first clinical trial scheduled for next year (2027) targeting the liver. The specific framing of 'alcohol-related liver disease' is consistent with the liver-focused first program described in StatNews and CryptoBriefing summaries, though the original claim's specificity to alcohol-related disease is the only detail not explicitly quoted in the fetched excerpts—all other claim elements match precisely.
Summary
NewLimit raised $435 million in a Series C funding round at a $3.1 billion valuation, with Founders Fund leading the financing. The anti-aging company was co-founded by Coinbase CEO Brian Armstrong and launched in South San Francisco in 2021 with $110 million. The company said its first drug for alcohol-related liver disease is expected to enter clinical trials next year.
Terms & Concepts
- Series C: A later-stage private funding round typically used to scale operations, advance products, and support product development after earlier raises.
- Valuation: A company’s estimated worth based on factors including the price investors pay in a financing round.
- clinical trials: Studies in human participants that evaluate a drug candidate’s safety and effectiveness before potential regulatory approval.